Table 1.
Baseline clinical characteristics of the study cohort
| Parameters | Healthy subjects (n = 120) | CHB patients (n = 100) | LC patients (n = 90) | HCC patients (n = 104) |
|---|---|---|---|---|
| Age (yr) | 47.9 (34, 59) | 48.9 (35, 62) | 46.1 (36, 60) | 47.6 (33, 64) |
| Gender (Male %) | 80 (66.7) | 66 (66.0) | 58 (64.4) | 68 (65.4) |
| ALT (U/L) | 25 (8, 41) | 71 (30, 151) | 97 (39, 203) | 63 (16, 358) |
| Albumin (g/L) | 40.1 (35.2, 49.8) | 38.1 (30.6, 47.1) | 28.1 (18.4, 31.7) | 33.3 (18.8, 35.8) |
| TBIL (μmol/L) | 9.8 (3.1, 16.5) | 50.2 (9.2, 96.8) | 76.4 (9.2, 153.6) | 26.5 (5.3, 137.2) |
| Blood platelet count (×109/μL) | 19.2 (9.6, 35.7) | 15.8 (5.4, 23.1) | 5.3 (1.2, 12.8) | 9.6 (3.7, 19.5) |
| HBeAg (+) | 0 (0) | 56 (56.0) | 50 (55.6) | 54 (51.9) |
| HBV DNA (log10 copies/mL) | 0 | 5.9 (4.8, 7.1) | 5.8 (4.5, 6.8) | 5.7 (3.8, 7.5) |
Abbreviations: CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; TBIL, total bilirubin; HBeAg, HBV e-antigen. There were significantly different levels of ALT, albumin, TBIL and blood platelet count among the 4 groups (P < 0.05). All data are presented as the median (IQR) or n (%).